1. Home
  2. CASI vs ANTX Comparison

CASI vs ANTX Comparison

Compare CASI & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASI
  • ANTX
  • Stock Information
  • Founded
  • CASI 1991
  • ANTX 2017
  • Country
  • CASI China
  • ANTX United States
  • Employees
  • CASI N/A
  • ANTX N/A
  • Industry
  • CASI Biotechnology: Pharmaceutical Preparations
  • ANTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CASI Health Care
  • ANTX Health Care
  • Exchange
  • CASI Nasdaq
  • ANTX Nasdaq
  • Market Cap
  • CASI 35.8M
  • ANTX 31.4M
  • IPO Year
  • CASI 1996
  • ANTX 2022
  • Fundamental
  • Price
  • CASI $2.01
  • ANTX $1.28
  • Analyst Decision
  • CASI Strong Buy
  • ANTX Buy
  • Analyst Count
  • CASI 1
  • ANTX 2
  • Target Price
  • CASI $4.00
  • ANTX $2.00
  • AVG Volume (30 Days)
  • CASI 76.1K
  • ANTX 110.6K
  • Earning Date
  • CASI 11-13-2025
  • ANTX 11-12-2025
  • Dividend Yield
  • CASI N/A
  • ANTX N/A
  • EPS Growth
  • CASI N/A
  • ANTX N/A
  • EPS
  • CASI N/A
  • ANTX N/A
  • Revenue
  • CASI $31,564,000.00
  • ANTX N/A
  • Revenue This Year
  • CASI N/A
  • ANTX N/A
  • Revenue Next Year
  • CASI N/A
  • ANTX N/A
  • P/E Ratio
  • CASI N/A
  • ANTX N/A
  • Revenue Growth
  • CASI 36.64
  • ANTX N/A
  • 52 Week Low
  • CASI $1.09
  • ANTX $0.98
  • 52 Week High
  • CASI $7.50
  • ANTX $1.68
  • Technical
  • Relative Strength Index (RSI)
  • CASI 50.04
  • ANTX 61.69
  • Support Level
  • CASI N/A
  • ANTX $1.22
  • Resistance Level
  • CASI $2.49
  • ANTX $1.33
  • Average True Range (ATR)
  • CASI 0.17
  • ANTX 0.08
  • MACD
  • CASI -0.14
  • ANTX 0.01
  • Stochastic Oscillator
  • CASI 80.40
  • ANTX 82.14

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Share on Social Networks: